<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563355</url>
  </required_header>
  <id_info>
    <org_study_id>CRE2000.241</org_study_id>
    <secondary_id>HARECCTR0500004</secondary_id>
    <nct_id>NCT00563355</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients</brief_title>
  <official_title>A Prospective Randomised Controlled Trial to Study the Effects of Recombinant Human Erythropoietin on the Progression of Atherosclerosis, Cardiovascular Function, Nutrition and Residual Renal Function in Pre-dialysis Chronic Renal Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Authority, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hong Kong Society of Nephrology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Authority, Hong Kong</source>
  <brief_summary>
    <textblock>
      The primary aim of the study is to evaluate the effects of correction of anemia using
      erythropoietin on the progression of atherosclerosis and cardiac muscle thickening in
      patients with chronic kidney disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial function and atherosclerosis</measure>
    <time_frame>6 month, 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiac hypertrophy and cardiac function</measure>
    <time_frame>6 month, 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>nutrition status</measure>
    <time_frame>6 month, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>residual renal function</measure>
    <time_frame>6 month, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>6 month, 1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">66</enrollment>
  <condition>Chronic Disease</condition>
  <condition>Kidney Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erythropoietin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic renal failure with serum creatinine between 150umol/L and
             800umol/L and at the same time Hb

          -  Patients with regression line of 1/serum creatinine versus time showing that they may
             not require dialysis within the coming 12 months

          -  Patients below the age of 75

        Exclusion Criteria:

          -  Patients with valvular heart disease/congenital heart disease

          -  Patients with ischemic heart disease/history of myocardial infarction/coronary artery
             bypass surgery

          -  Patients with history of heart failure

          -  Patients with regression line of 1/serum creatinine versus time showing that the
             estimated date of end stage renal disease is within 12 months

          -  Patients with thalassemic trait or haemoglobinopathies

          -  Patients with underlying haematological malignancies

          -  Patients with active bleeding

          -  Patients with uncorrected iron or other vitamins deficiencies

          -  Patients with poor general condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Angela YM Wang, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine &amp; Therapeutics/Nephrology, Prince of Wales Hospital/ The Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>June 14, 2011</last_update_submitted>
  <last_update_submitted_qc>June 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2011</last_update_posted>
  <keyword>chronic kidney disease</keyword>
  <keyword>cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

